 |
 |
 |
Midkine Strategy
...MTY completed its Midkine Commercial Developement Strategy...
Convertible Notes Resolved
MTY has finalised an agreement with holders of MTY Convertible Notes ...
Major US Patent Granted
...“Agents Comprising Midkine or an Inhibitor Thereof as Active Ingredient”...
Analyst Report and Interactive Roadshow Released
... first online Interactive Investor Roadshow eKit ...
Midkine Test Validated
... Revenue Generating Veterinary Midkine Test Validated....
MTY Shareholder News October 2008
MTY Shareholder News
Removal of $1.5M potential liability
MTY and Cell Signals Inc., have signed an amendment to the IP Agreement
Results of General Meeting 5 May 2009
Results of General Meeting of Members ...
|
 |
 |
 |
 |
Medical Therapies Ltd
(MTY):
 |
 |
 |
|
 |
 |
Medical Therapies Limited (ASX:MTY) is a listed Australian biotechnology company committed to the commercialization of midkine, a heparin-binding growth factor, and its inhibitors for both therapeutic and diagnostic applications.
MTY is actively looking for partners to commercialise the Company’s significant anti-midkine antibody portfolio for diagnostic and therapeutic purposes. In addition, MTY will also be looking for partnerships to continue to research anti-midkine antisense and siRNA.
MTY holds the largest intellectual property portfolio globally in relation to midkine, a significant therapeutic and diagnostic target.
2008 Medical Therapies Ltd Annual Report
& Notice of Annual General Meeting
Join our Mailing List
We invite you to receive our news electronically
|
 |
|